Zenas BioPharma Q2 2026: $673.9M Cash, FDA BLA Accepted, CFO Transition
ZBIO has more than doubled off its 52-week low of $13.5.
Summary
Zenas BioPharma's Q2 2026 10-Q shows $673.9M in cash, FDA acceptance of its obexelimab BLA, and a CFO transition. The company's runway extends into 2029.
Key Events · Earnings and Guidance · ZBIO
-
Cash Runway Extended
Cash, cash equivalents, and investments totaled $673.9 million as of June 30, 2026, sufficient to fund operations into 2029.
-
FDA Accepts BLA
The FDA accepted the obexelimab BLA for IgG4-RD with a PDUFA target date of May 27, 2027.
-
CFO Transition
Jennifer Fox will transition from CFO to Strategic Advisor effective September 30, 2026; Joseph Farmer appointed principal financial officer.
-
Subsequent Events
In July 2026, the company sold 1,818,181 shares via ATM for $48.7M net proceeds. In August 2026, BMS achieved a regulatory milestone triggering a $10.0M payment to Zenas and a $2.5M payment to Xencor. InnoCare near-term milestone of $25.0M and 2,000,000 shares to be issued.
Analysis · ZBIO · Life Sciences
A clinical-stage biotech's lifeline is its cash position and regulatory momentum. Zenas BioPharma reported Q2 2026 results with $673.9 million in cash and investments, extending runway into 2029. The FDA accepted the obexelimab BLA for IgG4-RD with a PDUFA date of May 27, 2027. The company also disclosed a CFO transition and subsequent events including an ATM sale and milestone payments. These developments are critical for assessing the company's near-term prospects.
At the time of this filing, ZBIO was trading at $31.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $13.50 to $44.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.